Trial Profile

Multicenter Randomized Phase II Study Comparing the Effectiveness and Tolerance of Avelumab Versus Standard 2nd Line Treatment Chemotherapy in Patients With Colorectal Metastatic Cancer With Microsatellite Instability (MSI)

Status: Active, no longer recruiting

Phase of Trial: Phase II

Latest Information Update: 03 Oct 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Avelumab (Primary) ; Aflibercept; Bevacizumab; Cetuximab; Fluorouracil; Folinic acid; Irinotecan; Oxaliplatin; Panitumumab
Indications Adenocarcinoma; Colorectal cancer
Focus Therapeutic Use
Acronyms SAMCO-PRODIGE 54

13 Sep 2022 Primary endpoint has been met. (Progression-free survival (PFS) according to the investigator), as per Results presented at the 47th European Society for Medical Oncology Congress
13 Sep 2022 Results presented at the 47th European Society for Medical Oncology Congress
07 Sep 2022 According to Merck & Co media release, results from this trial will be presented at European Society of Medical Oncology (ESMO) 2022 (LBA23).

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com